Eli Lilly’s Verzenios (abemaciclib) has received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), in combination with endocrine therapy for the adjuvant treatment of patients with HR+, HER2-, high risk node-positive early breast cancer (EBC).
Breast cancer is the most common cancer among women worldwide, with 20-30% of patients diagnosed with HR+ or HER2- early breast cancer that could progress to incurable metastatic disease…
